-
公开(公告)号：US09914727B2
公开(公告)日：2018-03-13
申请号：US14652174
申请日：2013-12-16
发明人： Cameron James Smith , John Qiang Tan , Ting Zhang , James Balkovec , William John Greenlee , Liangqin Guo , Yi-Heng Chen , Yili Chen , Samuel Chackalamannil , Tomokazu Hirabayashi , Mika Sekioka
IPC分类号： C07D413/14 , C07D413/12 , C07D513/04
CPC分类号： C07D413/14 , C07D413/12 , C07D513/04
摘要： The present invention provides compounds of Formula (I) and pharmaceutical compositions comprising compounds of Formula I, and methods for using compounds of Formula I for treating or preventing thromboses, embolisms, hypercoaguability or fibrotic changes.
-
公开(公告)号：US09902723B2
公开(公告)日：2018-02-27
申请号：US15329467
申请日：2015-07-29
发明人： Tsutomu Satoh , Takashi Kudoh , Tetsuo Iwama
IPC分类号： A61K31/506 , C07D471/04 , C07D403/04 , C07D417/04
CPC分类号： C07D471/04 , A61K31/427 , A61K31/506 , C07D403/04 , C07D417/04
摘要： The present invention provides a method for manufacturing a compound represented by formula (I). With this method, provided is a method for manufacturing a 4-substituted-N-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-1H-pyrazole-5-carboxylic acid amide derivative; or an intermediate for this manufacturing method.
-
公开(公告)号：US20180030036A1
公开(公告)日：2018-02-01
申请号：US15534029
申请日：2015-12-07
申请人： Ting ZHANG , Yi-Heng CHEN , Liangqin GUO , Alan HARUZA , Tianying JIAN , Bing LI , Dongfang MENG , Dann L. PARKER, JR. , Edward C. SHERER , Harold B. WOOD , Isao SAKURADA , MERCK SHARP & DOHME CORP. , MOCHIDA PHARMACEUTICAL CO., LTD
发明人： Ting Zhang , Yi-Heng Chen , Liangqin Guo , Alan Hruza , Tianying Jian , Bing Li , Dongfang Meng , Dann L. Parker , Edward C. Sherer , Harold B. Wood , Isao Sakurada
IPC分类号： C07D403/12 , C07D401/14 , C07D401/12 , C07D471/04
CPC分类号： C07D403/12 , C07D401/12 , C07D401/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04
摘要： The present invention provides a compound of Formula I, and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels. The compounds are selective Factor IXa inhibitors.
-
公开(公告)号：US20180015038A1
公开(公告)日：2018-01-18
申请号：US15545178
申请日：2016-01-20
发明人： Hiromitsu ITO , Hirosato FUJII , Motoo YAMAGATA , Daichi TANAKA
IPC分类号： A61K9/107 , A61K47/24 , A61K31/505 , A61K9/48 , A61K31/47 , A61K31/232 , A61K47/44 , A61K47/14
CPC分类号： A61K9/107 , A61K9/1075 , A61K9/4825 , A61K9/4858 , A61K31/232 , A61K31/47 , A61K31/505 , A61K47/14 , A61K47/24 , A61K47/26 , A61K47/44 , A61K2300/00
摘要： A pharmaceutical composition comprising, in relation to 100% by weight of a total amount of a self-emulsifying composition, 70 to 90% by weight of eicosapentaenoic acid ethyl ester as a first medicinal component, 0.5 to 6% by weight of water, 1 to 29% by weight of polyoxyethylene sorbitan fatty acid ester (optionally further comprising polyoxyethylene castor oil) as an emulsifier, 1 to 25 parts by weight of lecithin in relation to 100 parts by weight of the eicosapentaenoic acid ethyl ester, and pitavastatin, rosuvastatin, or a salt thereof as a second medicinal component. The composition is excellent in any one of self-emulsifying property, dispersibility of the composition, emulsion stability, absorbability, and storage stability of the medicinal components and a preparation.
-
公开(公告)号：US09801843B2
公开(公告)日：2017-10-31
申请号：US14905520
申请日：2014-07-17
发明人： Shigeru Kimura , Hiromitsu Ito , Hirosato Fujii , Motoo Yamagata
IPC分类号： A61K9/107 , A61K47/44 , A61Q19/00 , A61K31/202 , A61K31/232 , A61K47/26 , A61K9/48 , A61K47/10 , A61K47/14 , A23L29/10 , A23L33/115
CPC分类号： A61K31/202 , A23L29/10 , A23L33/115 , A61K9/1075 , A61K9/4858 , A61K31/232 , A61K47/10 , A61K47/14 , A61K47/26
摘要： A self-emulsifying composition contains: 70 to 90% by weight in total of one or more compounds selected from the group consisting of ω3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; 1 to 29% by weight of an emulsifying agent selected from among a polyoxyethylene sorbitan fatty acid ester, a sorbitan fatty acid ester, a glycerin fatty acid ester and a polyoxyl castor oil; and 0.5 to 6% by weight of water when the composition is defined to be 100% by weight as a whole. The self-emulsifying composition is excellent in self-emulsifying property, composition dispersibility, emulsion stability, and absorbability, is free from ethanol and polyhydric alcohols or only has such an alcohol added thereto at a reduced concentration, and is useful for foods and pharmaceuticals.
-
公开(公告)号：US09777000B2
公开(公告)日：2017-10-03
申请号：US15234730
申请日：2016-08-11
发明人： Akihiro Okano , Kouki Ogawa
IPC分类号： C07D471/04 , C07D401/04 , C07D417/04 , A61K31/437 , A61K31/444 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D403/04
CPC分类号： C07D471/04 , A61K31/437 , A61K31/444 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D401/04 , C07D403/04 , C07D417/04
摘要： It has been desired to develop a pharmaceutical composition, which is used in agents for preventing and/or treating various diseases related to PDE10 (e.g. mental disorder and neurodegenerative disorder). The present invention provides: compounds having PDE10 inhibitory effect, in particular, compounds having a 4-heteroarylpyrazole-5-carboxylic acid amide structure represented by the following formula (I), or their pharmaceutically acceptable salts, or their solvates; pharmaceutical compositions comprising, as active ingredients, the compounds, or their pharmaceutically acceptable salts, or their solvates; and medical use of the compounds, or their pharmaceutically acceptable salts, or their solvates.
-
公开(公告)号：US09700538B2
公开(公告)日：2017-07-11
申请号：US14400777
申请日：2013-05-14
IPC分类号： A61K31/232 , A61K31/202 , G01N33/68 , G01N33/92 , G01N30/88
CPC分类号： A61K31/232 , A61K31/202 , G01N33/6893 , G01N33/92 , G01N2030/8813 , G01N2333/4737 , G01N2800/2871 , G01N2800/32 , G01N2800/324 , G01N2800/325
摘要： The present invention provides the following: a cardiovascular disease primary prevention agent, which comprises as the active ingredient at least one selected from the group consisting of EPA, salts thereof, and esters thereof and is for lowering the risk of cardiovascular disease by administration to subjects having a blood (serum or plasma) hs-CRP level of 1.0 mg/L or higher in spite of no history of cardiovascular disease; a combination marker comprising the blood hs-CRP value and serum EPA/AA ratio for evaluating the primary risk of cardiovascular disease in subjects having no history of cardiovascular disease; and a method for extracting subjects with high risk of cardiovascular disease and/or a method for preventing cardiovascular disease.
-
公开(公告)号：US09603805B2
公开(公告)日：2017-03-28
申请号：US14345708
申请日：2011-09-30
申请人： Yumio Kudou , Kuniomi Warabino , Hiromitsu Ito
发明人： Yumio Kudou , Kuniomi Warabino , Hiromitsu Ito
IPC分类号： A61K9/28 , A61K9/20 , A61K31/522 , A61K31/5383
CPC分类号： A61K9/2866 , A61K9/0053 , A61K9/2072 , A61K9/2813 , A61K9/282 , A61K9/2826 , A61K9/284 , A61K9/286 , A61K9/2886 , A61K31/522 , A61K31/5383
摘要： It has been desired to develop a coating composition, which is used for an orally-administered preparation having an improved administering property, and/or an easily administrable preparation that does not affect dissolution property. The present invention provides a coating composition comprising: a first thickener selected from the group consisting of a carboxyvinyl polymer and sodium alginate; a polyvalent metal compound; at least one type of a second thickener selected from the group consisting of xanthan gum, guar gum and sodium alginate, with the proviso that when the first thickener is sodium alginate the second thickener is not sodium alginate; and sucralose.
-
公开(公告)号：US20160347751A1
公开(公告)日：2016-12-01
申请号：US15234730
申请日：2016-08-11
发明人： Akihiro OKANO , Kouki OGAWA
IPC分类号： C07D471/04
CPC分类号： C07D471/04 , A61K31/437 , A61K31/444 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D401/04 , C07D403/04 , C07D417/04
摘要： It has been desired to develop a pharmaceutical composition, which is used in agents for preventing and/or treating various diseases related to PDE10 (e.g. mental disorder and neurodegenerative disorder). The present invention provides: compounds having PDE10 inhibitory effect, in particular, compounds having a 4-heteroarylpyrazole-5-carboxylic acid amide structure represented by the following formula (I), or their pharmaceutically acceptable salts, or their solvates; pharmaceutical compositions comprising, as active ingredients, the compounds, or their pharmaceutically acceptable salts, or their solvates; and medical use of the compounds, or their pharmaceutically acceptable salts, or their solvates.
-
公开(公告)号：US09476872B2
公开(公告)日：2016-10-25
申请号：US12994109
申请日：2009-05-22
申请人： Katsuki Naito
发明人： Katsuki Naito
IPC分类号： C12Q1/02 , G01N33/53 , G01N33/50 , C07K14/705 , G01N33/569
CPC分类号： G01N33/56972 , C07K14/70596 , C07K16/2896 , G01N33/5047 , G01N33/5091 , G01N2333/70596 , G01N2800/00
摘要： A novel convenient method for evaluating the function of a phagocyte is provided. The method assays sCD14-ST, which is a humoral factor specifically produced in phagocytosis by the phagocyte and which is stable enough for use in an assay. Also provided is a method for detecting diseases associated with the phagocytosis by the phagocyte.
摘要翻译： 提供了一种评估吞噬细胞功能的新颖方便方法。 方法测定sCD14-ST，其是通过吞噬细胞吞噬特异性产生并且足够稳定以用于测定中的体液因子。 还提供了用于检测与吞噬细胞吞噬有关的疾病的方法。
-
-
-
-
-
-
-
-
-
搜索结果
358 条记录 (耗时 0.052 秒)
